Dhote Lokesh, Dewangan Hitesh Kumar
University Institute of Pharma Sciences (UIPS), Chandigarh University, NH-95 Chandigarh Ludhiana Highway, Mohali, Punjab, India.
Curr Pharm Des. 2025;31(22):1743-1754. doi: 10.2174/0113816128341348241224065313.
Schizophrenia is a heterogeneous neuropsychological disorder characterized by three distinct sets of symptoms: positive, negative, and cognitive. It carries significant public health implications and is estimated to affect up to 1% of the population. Despite extensive research, the underlying mechanisms of schizophrenia are not entirely understood, and existing antipsychotic treatments have notable limitations. Firstly, these treatments are effective for only approximately half of the patients. Secondly, they primarily alleviate positive symptoms such as misperceptions and thought disorders, which are core to the illness, while neglecting the negative symptoms like flat affect and social withdrawal, as well as cognitive symptoms such as learning and attention difficulties. Thirdly, these treatments come with significant neurofunctional and metabolic side effects, and in some cases, they can lead to issues like sexual dysfunction or agranulocytosis (in the case of Clozapine (CLZ)). In this review, we delve into currently available treatments for schizophrenia, with the utilization of Deep brain stimulation techniques to overcome the limitations of antipsychotics. We also discuss the major clinical trials for schizophrenia along with deep brain stimulation intervention.
精神分裂症是一种异质性神经心理障碍,其特征在于三组不同的症状:阳性、阴性和认知症状。它对公共卫生具有重大影响,估计影响高达1%的人口。尽管进行了广泛的研究,但精神分裂症的潜在机制尚未完全了解,现有的抗精神病药物治疗存在明显局限性。首先,这些治疗仅对大约一半的患者有效。其次,它们主要缓解如错觉和思维紊乱等阳性症状,这些是该疾病的核心症状,而忽视了如情感平淡和社交退缩等阴性症状,以及如学习和注意力困难等认知症状。第三,这些治疗伴有显著的神经功能和代谢副作用,在某些情况下,它们可能导致性功能障碍或粒细胞缺乏症(如使用氯氮平(CLZ)时)等问题。在本综述中,我们深入探讨目前可用的精神分裂症治疗方法,利用深部脑刺激技术来克服抗精神病药物的局限性。我们还讨论了精神分裂症的主要临床试验以及深部脑刺激干预。